---
figid: PMC5969374__blood764332f5
figtitle: Disrupted signaling pathways in ABC-DLBCL
organisms:
- Homo sapiens
organisms_ner:
- Homo sapiens
- Danio rerio
pmcid: PMC5969374
filename: blood764332f5.jpg
figlink: /pmc/articles/PMC5969374/figure/F5/
number: F5
caption: Disrupted signaling pathways in ABC-DLBCL. ABC-DLBCL is defined by multiple
  genetic alterations that fuel malignant transformation by sustaining constitutive
  NF-κB activity downstream of the BCR and TLR, while blocking terminal B-cell differentiation.
  Genes directly targeted by these lesions are shown in blue (inactivation) and red
  (deregulated expression/activity), and symbols at the bottom denote gain-of-function
  and loss-of-function events. Upstream inhibitors of the BCR, PI3K, and NF-κB signal
  transduction pathway have shown promising effects in early clinical trials involving
  ABC-DLBCL patients. Modified from Pasqualucci and Dalla-Favera with permission.
papertitle: Genetics of diffuse large B-cell lymphoma.
reftext: Laura Pasqualucci, et al. Blood. 2018 May 24;131(21):2307-2319.
year: '2018'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9549421
figid_alias: PMC5969374__F5
figtype: Figure
redirect_from: /figures/PMC5969374__F5
ndex: 06a9068f-deec-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5969374__blood764332f5.html
  '@type': Dataset
  description: Disrupted signaling pathways in ABC-DLBCL. ABC-DLBCL is defined by
    multiple genetic alterations that fuel malignant transformation by sustaining
    constitutive NF-κB activity downstream of the BCR and TLR, while blocking terminal
    B-cell differentiation. Genes directly targeted by these lesions are shown in
    blue (inactivation) and red (deregulated expression/activity), and symbols at
    the bottom denote gain-of-function and loss-of-function events. Upstream inhibitors
    of the BCR, PI3K, and NF-κB signal transduction pathway have shown promising effects
    in early clinical trials involving ABC-DLBCL patients. Modified from Pasqualucci
    and Dalla-Favera with permission.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CD40LG
  - CD79A
  - BCR
  - RN7SL263P
  - IBTK
  - TLR1
  - TLR2
  - TLR3
  - TLR4
  - TLR5
  - TLR6
  - TLR7
  - TLR8
  - TLR9
  - TLR10
  - IL1R1
  - CD40
  - BTK
  - SYK
  - CARD11
  - PRKCB
  - BCL10
  - MYD88
  - MALT1
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - SOAT1
  - STAT1
  - STAT2
  - STAT3
  - STAT4
  - STAT6
  - STAT5A
  - STAT5B
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - NFKB1
  - AKT1
  - AKT2
  - AKT3
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - CRK
  - AIMP2
  - GRAP2
  - AHSA1
  - POLDIP2
  - IRF4
  - MTOR
  - IFNK
  - IFNW1
  - IFNA1
  - IFNA2
  - IFNA4
  - IFNA5
  - IFNA6
  - IFNA7
  - IFNA8
  - IFNA10
  - IFNA13
  - IFNA14
  - IFNA16
  - IFNA17
  - IFNA21
  - IFNB1
  - BCL6
  - cd79a
  - bcr
  - il1rl1
  - cd40
  - btk
  - syk
  - card11
  - prkcbb
  - bcl10
  - myd88
  - malt1
  - malt2
  - stat1b
  - stat4
  - mapk14a
  - mtor
  - bcl6aa
  - Enzastaurin
  - Bortezomib
  - Lenalidomide
  - Everolimus
  - Temsirolimus
  - Cancer
---
